Iodixanol
- Generic Name
- Iodixanol
- Brand Names
- Visipaque, Visipaque 270, Visipaque 320
- Drug Type
- Small Molecule
- Chemical Formula
- C35H44I6N6O15
- CAS Number
- 92339-11-2
- Unique Ingredient Identifier
- HW8W27HTXX
- Background
Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents.
- Indication
Iodixanol is a contrast agent during coronary angiography.
A Clinical Study of Xenetix 300 in Multislice Computed Tomography (CT) Pediatric Indications
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2013-04-09
- Lead Sponsor
- Guerbet
- Target Recruit Count
- 145
- Registration Number
- NCT00347022
- Locations
- 🇫🇷
CHU Charles Nicolle, Rouen, France
Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2019-04-25
- Lead Sponsor
- GE Healthcare
- Target Recruit Count
- 66
- Registration Number
- NCT00348608
Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart
- First Posted Date
- 2006-06-09
- Last Posted Date
- 2019-04-25
- Lead Sponsor
- GE Healthcare
- Target Recruit Count
- 89
- Registration Number
- NCT00335335
Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography
Phase 4
Terminated
- Conditions
- Renal InsufficiencyDiabetes Mellitus
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2014-10-17
- Lead Sponsor
- GE Healthcare
- Target Recruit Count
- 656
- Registration Number
- NCT00209417
- Locations
- 🇬🇧
GE Healthcare, Amersham, United Kingdom
Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Coronary Angiography
Phase 4
Completed
- Conditions
- Coronary Artery DiseaseRenal Impairment
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2007-10-31
- Lead Sponsor
- GE Healthcare
- Target Recruit Count
- 408
- Registration Number
- NCT00209430
- Locations
- 🇸🇪
Amersham Health S.A, Solna, Sweden
Iodixanol in Multidetector-Row Computed Tomography-Coronary Angiography (MDCT-CA)
Phase 4
Completed
- Conditions
- Coronary Artery Disease
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2007-10-31
- Lead Sponsor
- GE Healthcare
- Target Recruit Count
- 50
- Registration Number
- NCT00209404
- Locations
- 🇫🇷
Amersham Health S.A., Velizy Cedex, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath